

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

SEC FILE NUMBER: 001-39871  
CUSIP NUMBER: 78397T202

(Check One):  Form 10-K  Form 20-F  Form 11-K  Form 10-Q  Form 10-D  Form N-CEN  Form N-CSR

For Period Ended: March 31, 2024

Transition Report on Form 10-K

Transition Report on Form 20-F

Transition Report on Form 11-K

Transition Report on Form 10-Q

For the Transition Period Ended: \_\_\_\_\_

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

**SAB Biotherapeutics, Inc.**

Full Name of Registrant

N/A

Former Name if Applicable

777 W 41st St, Suite 401

Address of Principle Executive Office (*Street and Number*)

Miami Beach, Florida 33140

City, State and Zip Code

---

---

---

**PART II — RULES 12B-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III—NARRATIVE**

State below in reasonable detail why forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Registrant requires additional time to complete the preparation of its financial statements for the period ended March 31, 2024, to have them properly certified by the executive officers and have them reviewed by its independent auditors. The Registrant will file the Form 10-Q by the fifth calendar day following the required filing date, as prescribed in Rule 12b-25.

**PART IV—OTHER INFORMATION**

- (1) Name and telephone number of person to contact in regard to this notification

Michael G. King, Jr.

(Name)

(305)

(Area Code)

845-2813

(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).  Yes  No
- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  Yes  No
-

**SAB Biotherapeutics, Inc.**

(Name of Registrant as Specified in Charter)

---

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date May 15, 2024

By /s/ Michael G. King, Jr.  
Chief Financial Officer

---